Fraunhofer Venture
Hansastraße 27c, Munich, Bavaria, 80686, Germany
Overview
Fraunhofer Venture acts as a partner of founders, start-up companies, Fraunhofer institutes and investors. By offering access to Fraunhofer technologies, infrastructure and know-how with more than 4,500 patent classes, it provides young companies with the opportunity of a faster and better establishment of their products on the markets.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Financial Services
- Venture Capital
Investment portfolio
- Cellbox Solutions
Participated · Series A · Mar 2023
Founded in 2017 and headquartered in Cologne, Germany, Cellbox Solutions offers patented warm-chain technology that keeps cell samples at stable physiological conditions for up to 48 hours during transit. Its flagship Cellbox™ devices function as portable CO₂ incubators, allowing pharmaceutical and biotechnology companies, research institutions, and universities to ship living cells, organoids, and tissues without freezing. More than 300 units are already deployed worldwide, underscoring early commercial traction. The systems are certified and compliant with International Air Transport Association regulations, broadening their applicability to global air transport. Newly raised funds will be used to scale international production and sales operations and to expand use cases across cell and gene therapies, IVF, and other life-science workflows. The company has also strengthened its leadership by appointing Dr. Bernd Muehlenweg as Chief Business Officer and Chief Financial Officer to guide the next growth phase.
- Subitec
Participated · Equity · Jul 2012
Subitec develops and manufactures fully automated photobioreactors for industrial-scale microalgae production. Its core product is the flat panel airlift reactor (FPA), designed to ensure all algal cells are optimally supplied with light and to meet the preconditions for commercial mass production. The company produces biomass from strains including Chlorella vulgaris, Isochrysis aff. galbana (clone T. iso), Haematococcus pluvialis and Phaeodactylum tricornutum. Subitec completed a €4.5M second financing and intends to use the proceeds to launch its bioreactors on the international market and to continue investing in R&D. Founded in 2000 as a spin-off of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), the company is led by Managing Director Dr. Peter Ripplinger.